Format

Send to

Choose Destination
J Am Acad Dermatol. 2006 Aug;55(2):324-7.

Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma.

Author information

1
Department of Dermatology, University of L'Aquila, Italy. peris@univaq.it

Abstract

BACKGROUND:

Imiquimod has been successfully used for treatment of various epithelial cutaneous neoplasms.

OBJECTIVE:

Our aim was to evaluate the efficacy and tolerability of imiquimod 5% cream for treatment of Bowen's disease and invasive squamous cell carcinoma (SCC) in patients who were unsuitable candidates for surgery.

METHOD:

Five Bowen's disease lesions and 7 invasive SCC lesions on 10 patients were treated with imiquimod once daily 5 times a week for a maximum of 16 weeks.

RESULTS:

After 8 to 12 weeks of treatment, 4 of 5 Bowen's disease lesions (80%) and 5 of 7 invasive SCCs (71.4%) showed complete clinicopathologic regression. The remaining 3 lesions showed partial regression after 16 weeks of treatment. No recurrence has been detected after a follow-up period of 24 to 38 months (mean, 31 months).

LIMITATIONS:

The study is an open-label clinical trial on a small number of selected patients, with lack of excision with serial step sections.

CONCLUSION:

Topical application of imiquimod 5% cream might represent an alternative topical treatment to surgery in selected cases of Bowen's disease and invasive SCC.

PMID:
16844522
DOI:
10.1016/j.jaad.2006.04.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center